50

JCWSCS 1 5 MAR 2004

.03/15/04 MON 14:18 FAX 610 270 5090

SKB

FILE COPY

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Office of Initial Patent Examination's Filing Receipt Corrections at (703) 746-9195 on the date shown below.

Audrey A. Boyd

Audrey Pour

Morch 15,200

Attorney Docket No.: P31938C2

No. of Pages: 3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Sasse et al.

Serial No.:

10/692,544

Filed:

October 24, 2003

For:

HYDRATE OF 5-[4-[2-(N-METHYL-N-(2-

PYRIDIL)AMINO)ETHOXY]BENZYL]THIAZOLIDINE-2,4-DIONE

MALEIC ACID SALT

REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents:

Attached herewith is a copy of the Filing Receipt issued by the United States Patent and Trademark Office with changes noted thereon.

Applicants respectfully request that the United States Patent and Trademark Office correct the noted errors and issue an amended Filing Receipt.

Please charge Deposit Account No. 19-2570 the sum of \$25.00 as required by 37 CFR 1.19(h) and charge any additional fees which may be required by this paper, or credit any overpayment, to said deposit account. A duplicate of this request is attached.

Respectfully submitted

Attorney for Applicants
Registration No. 40,072

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5012
Facsimile (610) 270-5090
N:kls\cases\p31938c2\Request for Corr Filing Recpt.doc



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS PO. Bax 1459

Alexandria, Virginia 22313-1450				

APPL NO. | FILING OR 371 | ART UNIT | FIL FEE REC'D | ATTY.DOCKET NO | 10/692.544 | 10/24/2003 | 1614 | 770 | P31938C2

AWINGS TOT CLMS IND CLMS

CONFIRMATION NO. 1157

GLAXOSMITHKLINE Corporate Intellectual Property - UW2220 P.O. Box 1539 King of Prussia, PA 19406-0939

FILING RECEIPT

OC000000011879895

Date Mailed: 02/11/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt Incorporating the requested corrections (if appropriate).

Applicant(s)

Michael John Sasse, TUNBRIDGE WELLS, UNITED KINGDOM, Paul David James Blackler, TUNBRIDGE, UNITED KINGDOM; David C. Lee, Linton, UNITED KINGDOM;

Tonbridge, UK

Assignment For Published Patent Application

SmithKline Beecham p.l.c.;

Domestic Priority data as claimed by applicant

This application is a CON of 10/072,096 02/07/2002 PAT 6,664,278

Which is a CON of 09/581,719 filed 6/16/00 (Abandoned)
Foreign Applications Which is a 371 of Intil App. No. PET/ER98/08/54

If Required, Foreign Filing License Granted: 02/05/2004

Projected Publication Date: 05/20/2004

Non-Publication Request: No

Early Publication Request: No

Title

Page 2 of 2

Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt

Preliminary Class

514

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).